PT3959211T - Compostos de 4h-pirrolo[3,2-c]piridin-4-ona - Google Patents

Compostos de 4h-pirrolo[3,2-c]piridin-4-ona

Info

Publication number
PT3959211T
PT3959211T PT207211962T PT20721196T PT3959211T PT 3959211 T PT3959211 T PT 3959211T PT 207211962 T PT207211962 T PT 207211962T PT 20721196 T PT20721196 T PT 20721196T PT 3959211 T PT3959211 T PT 3959211T
Authority
PT
Portugal
Prior art keywords
pyrrolo
pyridin
compounds
Prior art date
Application number
PT207211962T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Broad Inst Inc
Bayer Ag
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70456765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3959211(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Broad Inst Inc, Bayer Ag, Dana Farber Cancer Inst Inc filed Critical Broad Inst Inc
Publication of PT3959211T publication Critical patent/PT3959211T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT207211962T 2019-04-24 2020-04-22 Compostos de 4h-pirrolo[3,2-c]piridin-4-ona PT3959211T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838051P 2019-04-24 2019-04-24
US201962940036P 2019-11-25 2019-11-25

Publications (1)

Publication Number Publication Date
PT3959211T true PT3959211T (pt) 2026-04-23

Family

ID=70456765

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207211962T PT3959211T (pt) 2019-04-24 2020-04-22 Compostos de 4h-pirrolo[3,2-c]piridin-4-ona

Country Status (32)

Country Link
US (2) US12679836B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959211B1 (cg-RX-API-DMAC7.html)
JP (1) JP7641913B2 (cg-RX-API-DMAC7.html)
KR (1) KR102915019B1 (cg-RX-API-DMAC7.html)
CN (3) CN114127064B (cg-RX-API-DMAC7.html)
AU (1) AU2020262221B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019998B1 (cg-RX-API-DMAC7.html)
CA (1) CA3137218A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014022A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210530A (cg-RX-API-DMAC7.html)
DK (1) DK3959211T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP21077614A (cg-RX-API-DMAC7.html)
ES (1) ES3068321T3 (cg-RX-API-DMAC7.html)
FI (1) FI3959211T3 (cg-RX-API-DMAC7.html)
GE (2) GEAP202415804A (cg-RX-API-DMAC7.html)
HR (1) HRP20260409T1 (cg-RX-API-DMAC7.html)
IL (1) IL287390B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210285A1 (cg-RX-API-DMAC7.html)
LT (1) LT3959211T (cg-RX-API-DMAC7.html)
MA (1) MA55751B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021012987A (cg-RX-API-DMAC7.html)
PE (1) PE20220254A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552693A1 (cg-RX-API-DMAC7.html)
PL (1) PL3959211T3 (cg-RX-API-DMAC7.html)
PT (1) PT3959211T (cg-RX-API-DMAC7.html)
RS (1) RS68081B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111304UA (cg-RX-API-DMAC7.html)
TW (1) TWI849114B (cg-RX-API-DMAC7.html)
UA (1) UA130453C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020216781A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
MX2023003362A (es) * 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
EP4244225B1 (en) * 2020-11-11 2026-06-03 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl}oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション N-((r)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((s)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドによる治療方法
IL315739A (en) * 2022-03-24 2024-11-01 Scorpion Therapeutics Inc Methods of synthesizing egfr inhibitors
WO2023205595A2 (en) * 2022-04-20 2023-10-26 Celyn Therapeutics, Inc Egfr inhibitors in cancer treatment
CA3270236A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation
CA3270230A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Crystalline forms of her2/mutegfr inhibitors and process for their preparation
CN119264091B (zh) * 2024-09-04 2025-05-27 康龙化成手性医药技术(宁波)有限公司 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
JP2008291023A (ja) 2007-04-27 2008-12-04 Sumitomo Chemical Co Ltd アミド化合物とその用途
EP2188292B1 (en) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
CN101367801B (zh) 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
ES2722431T3 (es) 2014-12-08 2019-08-12 Bayer Pharma AG Novedosos compuestos de aril-cianoguanidina
WO2016100166A1 (en) 2014-12-15 2016-06-23 Bristol-Myers Squibb Company SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
CN107406417B (zh) * 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
US20250136599A1 (en) 2025-05-01
CL2021002770A1 (es) 2022-05-27
RS68081B1 (sr) 2026-05-29
DK3959211T3 (da) 2026-04-27
AU2020262221B2 (en) 2025-11-20
CN117946100A (zh) 2024-04-30
JP2022532850A (ja) 2022-07-20
ES3068321T3 (en) 2026-05-29
CN114127064A (zh) 2022-03-01
MA55751B1 (fr) 2026-04-30
CO2021014022A2 (es) 2022-03-29
WO2020216781A1 (en) 2020-10-29
IL287390B1 (en) 2025-07-01
BR112021019998A2 (cg-RX-API-DMAC7.html) 2021-12-07
UA130453C2 (uk) 2026-02-25
MX2021012987A (es) 2022-04-01
ECSP21077614A (es) 2021-11-30
CA3137218A1 (en) 2020-10-29
TWI849114B (zh) 2024-07-21
BR112021019998B1 (pt) 2024-01-16
CN114127064B (zh) 2023-12-26
HRP20260409T1 (hr) 2026-06-05
PE20220254A1 (es) 2022-02-16
EP3959211B1 (en) 2026-02-18
KR20220004103A (ko) 2022-01-11
JOP20210285A1 (ar) 2023-01-30
MA55751A (fr) 2022-03-02
LT3959211T (lt) 2026-06-10
FI3959211T3 (fi) 2026-04-01
CR20210530A (es) 2021-12-23
PH12021552693A1 (en) 2022-03-21
TW202106683A (zh) 2021-02-16
GEAP202415804A (en) 2024-02-12
DOP2021000216A (es) 2022-05-15
IL287390A (en) 2021-12-01
CN117986251A (zh) 2024-05-07
AU2020262221A1 (en) 2021-11-18
GEP20247648B (en) 2024-07-25
KR102915019B1 (ko) 2026-01-21
PL3959211T3 (pl) 2026-07-27
US12679836B2 (en) 2026-07-14
US20220298157A1 (en) 2022-09-22
JP7641913B2 (ja) 2025-03-07
IL287390B2 (en) 2025-11-01
SG11202111304UA (en) 2021-11-29
EP3959211A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
IL287390A (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
IL289186A (en) Compounds of 4,4a,5,7,8,8a - hexapyrido[4,3-b][1,4]oxazin-3-one as inhibitors of magl
IL276802B1 (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL291471A (en) Pyrimido[3,2-d]pyrimidine compounds as immunomodulators
IL289233A (en) Compounds 4,4a,5,7,8,8a -hexapyrido[4,3-b][4-1]oxazin-3-one as magl inhibitors
SG11202000789WA (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
ZA202110732B (en) Pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
IL280513A (en) Imidazo[2,1-B]pyridazines as TRK inhibitors
IL280661A (en) PYRROLO[2,3-B]PYRIDINE is mutated at position 4 as ERBB regulators that are useful in cancer therapy
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
ZA201804619B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
SI3923914T1 (sl) Formulacija afabicina, način izdelave zanj
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
IL279156A (en) History of hexahydropyrrolo[4,3-C]pyrrole useful as LOX inhibitors
IL289141A (en) Compounds 7,8 dihydro-4h-pyrazolo[3,4-c]azepin-6-one
HK40041290A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40027677A (en) 1, 2-dihydro-3h-pyrazolo [3, 4-d]pyrimidin-3-one analogs
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
HK40054941A (en) Pyridin-2-one compounds useful as smarca2 antagonists
HK40055110A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40055108A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK1262816A1 (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds